On ECHEMI
Home > Drugs > Shanghai New Hualian Pharmaceutical Co., Ltd.
Shanghai New Hualian Pharmaceutical Co., Ltd.
  • Founded in:

    2010-11-24
  • Country:

    China China
  • Address:

    No. 217, Minle Road, Xinghuo Development Zone, Haiwan Town, Fengxian District, Shanghai
  • Tax NO.:

    913101205648476887
  • Registered Funds:

    107.636649 yuan
  • Email:

Related Drugs
Gadopentetate dimeglumine
Name Description Content CAS NO. Registered Holders
Gadopentetate dimeglumine

Extract from the above information

More

Extract from the above information

86050-77-3 10
Medroxyprogesterone acetate
Name Description Content CAS NO. Registered Holders
Medroxyprogesterone Acetate

71-58-9 22
Medroxyprogesterone acetate
Name Description Content CAS NO. Registered Holders
Medroxyprogesterone Acetate

71-58-9 22
Diatrizoate
Name Description Content CAS NO. Registered Holders
Diatrizoic Acid Dihydrate

No specific pharmacological effects mentioned

More

No specific pharmacological effects mentioned

50978-11-5 11
Nylestradiol tablets
The main component of this product is nialstradiol. Its chemical name is: 3-(cyclopentyloxy)-19-nor-17-pregnane-1,3,5(10)-triene-20-yne-16α,17α-diol.
Name Description Content CAS NO. Registered Holders
Nilestriol

Estrogen drugs. This product is a derivative of estriol. Its pharmacological effects are similar to those of estradiol, but its biological activity is low, so its effect on endometrial proliferation is also weak. It is suitable for estrogen replacement therapy for perimenopausal women. The introduction of cyclopentyl ether at the 3rd position increases its lipophilicity, which is beneficial for intestinal absorption and storage in adipose tissue, and then slowly released to play a long-term effect. The introduction of acetylene at the 17th position enhances the estrogen activity.

More

Estrogen drugs. This product is a derivative of estriol. Its pharmacological effects are similar to those of estradiol, but its biological activity is low, so its effect on endometrial proliferation is also weak. It is suitable for estrogen replacement therapy for perimenopausal women. The introduction of cyclopentyl ether at the 3rd position increases its lipophilicity, which is beneficial for intestinal absorption and storage in adipose tissue, and then slowly released to play a long-term effect. The introduction of acetylene at the 17th position enhances the estrogen activity.

39791-20-3 2
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.